0 Items
Select Page

Bordetella pertussis

Bordetella Pertussis is the causative agent of whooping cough, a highly contagious respiratory disease, known for uncontrollable, violent coughing which often makes it hard to breathe.

Our Bordetella pertussis product range includes several formats of pertussis toxin and also purified FHA antigen. In addition to applications for vaccine research and within diagnostics kits, our toxin is highly active and widely used in cell biology studies of GTP binding proteins.

Bordetella pertussis Background

Bordetella Pertussis is a gram-negative coccobacillus that belongs to the genus Bordetella. First described in 1906, B. pertussis infection causes a highly contagious respiratory disease in humans, known as whooping cough or pertussis. The organism is thought to be transmitted between humans by aerosol droplets but does not survive for long periods in the environment.

Pertussis infection is localised to the respiratory tract and usually gives causes general malaise followed by a paroxysmal period of coughing lasting 1-6 weeks. Reports suggest that infection may cause an increase in lymphocyte numbers, causing confusion and other neurological symptoms. These symptoms may be caused by B. pertussis virulence factors (Hewlett, EL), which include pertussis toxin, filamentous haemagglutinin, pertactin, adenylate cyclase toxin and tracheal cytotoxin. Currently, the precise mechanism of pathogenesis is still unknown and the relevance of these and other potential virulence factors is still to be determined (CDC).

Until the introduction of a successful vaccine in the 1940s, whooping cough was a common illness in young children worldwide and a major cause of childhood mortality. Subsequent widespread vaccination resulted in a significant decrease in the number of cases worldwide. However, in recent years the number of reported cases have been rising in the developed world. Cases of infection have also been reported in adolescents, young adults and infants that are too young to vaccinate. These reports raise concerns regarding the efficacy of the vaccine currently in use and the possibility of waning immunity in vaccinated individuals (Hartzell, JD).

Currently, diagnosis of infection is achieved using serological techniques and molecular subtyping. However, correct diagnosis is complicated by the fact that symptoms of B. pertussis resemble other respiratory diseases in the early stages, driving a need for more sensitive methods of detection and diagnosis.

References

  1. Hewlett, EL (2014). Pertussis Pathogenesis—What We Know and What We Don’t Know. J Infect Dis.209(7): 982–985.
  2. Centers for Disease Control and Prevention: Pertussis (whooping cough)
  3. Hartzell, JD and Blaylock, JM (2014). Whooping cough in 2014 and beyond: an update and review. Chest.146(1):205-214.

Bordetella pertussis Antigens

The Native Antigen Company offers two key Bordetella pertussis antigens: the pertussis toxin, and filamentous haemagglutinin (FHA).

Pertussis toxin is most commonly used in immunoassay manufacture and cell biologists studying GTP receptor biology. To meet the variety of needs, we offer pertussis toxin in a range of different formats.

FHA is increasingly used in immunoassays, monitoring responses to pertussis vaccination.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

5 + 5 =

Live Customer Feedback